Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Momentum Rank : 0 (As of Jun. 20, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Momentum Rank?

Infant Bacterial Therapeutics AB has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Infant Bacterial Therapeutics AB Momentum Rank Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden 9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines